切换至 "中华医学电子期刊资源库"

中华妇幼临床医学杂志(电子版) ›› 2011, Vol. 07 ›› Issue (03) : 202 -205. doi: 10.3877/cma.j.issn.1673-5250.2011.03.004

论著

TCT标本检测高危HPV E6/E7mRNA及在宫颈病变中的应用研究
刘桐宇, 谢榕, Lulu Zhang, 郑雄伟, 陈刚, 何诚, 林玉珍, 杨琳, 李桑   
  1. 350014 福建福州,福建省肿瘤医院妇科
    美国纽约罗切斯特大学肿瘤放射中心
    350014 福建福州,福建省肿瘤医院病理科
  • 出版日期:2011-06-01

Practicability Study of Applying High-Risk Human Papilloma Virus E6/E7 mRNA Levels to Determine Cervical Lesion by Using ThinPrep Cytology Test Sample

Tong-yu LIU, Rong XIE, Lulu Zhang, Xiong-wei ZHENG, Gang CHEN, Cheng HE, Yu-zhen LIN, Lin YANG, Sang LI   

  1. Department of Gynecology, Fujian Tumor Hospital, Fuzhou 350014, Fujian Province, China
  • Published:2011-06-01
  • Supported by:
    * Project No. 2009-2-29, supported by the Fund for Young Scholars From Shangdong Provincial Health Department
引用本文:

刘桐宇, 谢榕, Lulu Zhang, 郑雄伟, 陈刚, 何诚, 林玉珍, 杨琳, 李桑. TCT标本检测高危HPV E6/E7mRNA及在宫颈病变中的应用研究[J/OL]. 中华妇幼临床医学杂志(电子版), 2011, 07(03): 202-205.

Tong-yu LIU, Rong XIE, Lulu Zhang, Xiong-wei ZHENG, Gang CHEN, Cheng HE, Yu-zhen LIN, Lin YANG, Sang LI. Practicability Study of Applying High-Risk Human Papilloma Virus E6/E7 mRNA Levels to Determine Cervical Lesion by Using ThinPrep Cytology Test Sample[J/OL]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2011, 07(03): 202-205.

目的

探讨新柏超薄液基细胞学检测(Thin-prep cytology test, TCT)标本检测高危人乳头瘤病毒(human papilloma virus, HPV) E6/E7 mRNA可行性及在宫颈癌筛查中的应用价值。

方法

两种标本处理方法,分别在22例经超薄液基细胞学技术标本检测HPV E6/E7 mRNA及HPV E6/E7 DNA;对108例不同病变程度宫颈癌标本采取超薄液基细胞学技术检测高危HPV (high-risk HPV, HR-HPV) E6/ E7 mRNA及高危HPV E6/E7 DNA,并行统计学处理。

结果

两种方法处理标本行Willcoxon配对秩和检验比较,差异无显著意义(P>0.05)。随着宫颈病变程度增加,HPV E6/E7 mRNA表达率相应增加。新柏液基细胞学技术检测108例标本高危HPV E6/E7 mRNA表达的相对拷贝数为320.554±779.104,高危HPV E6/E7 DNA为1540.963±3575.255,两者秩相关检验,相关系数为1。

结论

超薄液基细胞学检测标本可行高危HPV E6/E7 mRNA及HPV E6/E7 DNA检测;宫颈癌筛查检测HPV E6/E7 mRNA有一定临床意义。

Objective

To research the feasibility and clinical application value of high-risk human papilloma virus (HR-HPV) E6/E7 mRNA and DNA transcripts in cervical cancer samples by using liquid-based Thin-prep cytology test (TCT).

Methods

Both high-risk HPV E6/E7 mRNA and DNA of 22 samples by two different methods of Specimen handling were detected. The data from detection of high-risk HPV E6/E7 mRNA and HPV E6/E7 DNA in 108 TCT samples with different cervical lesions were statistically analyzed.

Results

Willcoxon rank test was used to exam two different methods of Specimen handling (P> 0.05). The expression level of HPV E6/E7 mRNA transcripts was related to the development of severe epithelial cervical dysplasia. The expression copy number of HPV E6/E7 mRNA transcripts in 108 Thin-prep cytology test was 320.554 ± 779.104. The expression copy number of HPV E6/E7 DNA transcripts in 108 Thin-prep cytology tests was 1540.963 ± 3575.255. The coefficient of Spearman test among HPV DNA and E6/E7 mRNA was 1.

Conclusions

The residual Thin-prep cytology test samples could be used in the detection of high-risk HPV E6/E7 mRNA and HPV E6/E7 DNA. HPV E6 and E7 mRNA test could be a useful tool for cervical cancer screening.

1 Munoz N, Castellsague X, de Gonzalez AB, et al. Chapter 1: HPV in the etiology of human cancer [J]. Vaccine, 2006, 24(Suppl 3): S3/1-10.
2 Brink AA, Snijders PJ, Meijer CJ, et al. HPV testing in cervical screening [J]. Best Pract Res Clin Obstet Gynaecol, 2006, 20(2):253-266.
3 Lie AK, Kristensen G. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical cancinoma[J]. Expert Rev Mol Diagn, 2008, 8(4): 405-415.
4 Castle PE, Dockter J, Giachetti C, et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer [J]. Clin Cancer Res, 2007, 13(9): 2599-2605.
5 Andersson S, Hansson B, Norman I, et al. Expression of E6/E7 mRNA from ' high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a [J]. Int J Oncol, 2006, 29(3):705-711.
6 Molden T, Nygard JF, Kraus I, et al. Predicting CIN2 + when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear [J]. Int J Cancer, 2005, 114(6): 973-976.
7 Sæterdal IM, Juvet LK, Norderhaug IN. HPV RNA test for cervical cancer [R]. Rapport fra Kunnskapssenteret, NOKC nr 02-2008.
8 Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia [J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(10):2536-2545.
9 Bianchi A, Moret F, Desrues JM, et al. PreservCyt transport me dium used for the ThinPrep Pap test is a suitable medium for detection of Chlamydia trachomatis by the COBAS Amplicor CT/NG test: Results of a preliminary study and future implications [J]. J Clin Microbiol, 2002, 40(5): 1749-1754.
10 Cattani P, Zannoni GF, Ricci C, et al. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix [J]. J Clin Microbiol, 2009, 47(12): 3895-3901.
11 Cattani P, Siddu A, D'Onghia S, et al. RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus [J]. J Clin Microbiol, 2009, 47 (7): 2136-2141.
12 Mockel J, Clad A, Endres AS, et al. HPV E6/E7 mRNA transcripts as predictors of high-grade epithelial cervix dysplasia [J]. Diagn Pathol, 2007, 2(Suppl 1) : S1.
13 Keegan H, Mc Inerney J, Pilkington L, et al. Comparison of HPV detection technologies: Hybrid capture 2, PreTectTM HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens [J]. J Virol Methods, 2009, 155(1): 61-66.
14 Oikonomou P, Messinis I, Tsezou A. DNA methylation is not likely to be responsible for hTERT expression in premalignant cervical lesions [J]. Exp Biol Med (Maywood), 2007, 232(7): 881-886.
15 Rosini S, Zappacosta R, Di Bonaventura G, et al. Management and triage of women with human papillomavirus infection in follow-up for low-grade cervical disease: Association of HPV-DNA AND RNA-based methods [J]. Int J Immunopathol Pharmacol, 2007, 20(2): 341-347.
[1] 刘洋, 盛赵莹, 孙琳琳. 白细胞介素6启动子通过调控人端粒酶逆转录酶减轻细胞炎症和DNA损伤[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(02): 104-110.
[2] 石皆春, 范子玉, 邢燕. 不同筛查方法预警宫颈原位腺癌的效能[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 575-581.
[3] 谭娟, 谭建新, 邵彬彬, 王艳, 许争峰. 胎儿单基因遗传病无创产前检测的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(03): 245-250.
[4] 蒋冉, 邹彩艳, 桑谊荃. 宫颈上皮内瘤变Ⅲ患者血清性激素水平及其与高危型人乳头瘤病毒感染的关系[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(06): 683-688.
[5] 陈海涛, 章敬尧, 朱冰, 管佳佳, 傅军. 血清循环DNA在胃癌中的诊断及预后的价值[J/OL]. 中华普通外科学文献(电子版), 2024, 18(01): 18-22.
[6] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[7] 刘静, 徐爽, 缪亚军. 肺腺癌miR-3653表达与高危型人乳头瘤病毒感染及预后的关系[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 600-604.
[8] 赵海燕, 靳海涛, 孔莺, 何瑞远. 血浆NGS-ctDNA对EGFR-TKIs治疗晚期NSCLC患者的预后意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(03): 385-391.
[9] 吴天秀, 徐瑜, 廖秀清, 姚伟, 王关嵩, 杨昱, 王斌, 郭亮, 张明周, 吴国明, 罗莉, 白莉, 王彦, 胡明冬, 徐智. 驱动基因阴性Ⅲ/Ⅳ期非小细胞肺癌BRCA1/2基因突变与含铂化疗疗效的关系[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(05): 615-623.
[10] 杨智義, 赵成俊, 胡欣芫, 潘佰猛, 张秋雨, 张挽乾, 曹芮, 张灵强. 外周血cfDNA液体活检技术在肝棘球蚴病诊治中的应用进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 389-393.
[11] 顾睿祈, 方洪生, 蔡国响. 循环肿瘤DNA检测在结直肠癌诊治中的应用与进展[J/OL]. 中华结直肠疾病电子杂志, 2023, 12(06): 453-459.
[12] 孙晗, 于冰, 武侠, 周熙朗. 基于循环肿瘤DNA 甲基化的结直肠癌筛查预测模型的构建与验证[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 500-506.
[13] 杨琬芳, 许晶, 张耀方, 王青, 杨智超, 任方刚, 王宏伟. NK和NKT细胞对急性髓系白血病患者的临床影响[J/OL]. 中华临床医师杂志(电子版), 2023, 17(09): 932-938.
[14] 李玛, 闫凌, 席云, 李尚霞, 朱冬林. HBV RNA用于监测慢性乙型肝炎患者临床治愈的研究和应用[J/OL]. 中华临床实验室管理电子杂志, 2024, 12(02): 70-74.
[15] 张续乾, 宫一凡, 翟爱军. 多靶点粪便DNA检测与噗噗管法FIT在体检人群结直肠癌筛查中的效果比较[J/OL]. 中华胃肠内镜电子杂志, 2024, 11(01): 33-36.
阅读次数
全文


摘要